Grace Therapeutics (GRCE) Convertible Debt (2019 - 2020)
Grace Therapeutics (GRCE) posted Convertible Debt of $187000.0 for Q1 2020, down 88.17% sequentially from $1.6 million in Q1 2019, and down 88.17% YoY from $1.6 million in Q2 2019.
Grace Therapeutics (GRCE) Convertible Debt (2019 - 2020) Analysis & Trends
Grace Therapeutics has reported Convertible Debt for 2 years, with the latest figure at $187000.0 in Q1 2020.
- Quarterly Convertible Debt fell 88.17% year-over-year to $187000.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $187000.0 (down 88.17% YoY) and the FY2020 annual result came in at $187000.0, down 88.17% from the prior year.
- Convertible Debt slipped to $187000.0 in Q1 2020 per GRCE's latest filing, from $1.6 million in the prior quarter.
- Over five years, Convertible Debt peaked at $1.6 million in Q1 2019 and troughed at $187000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 187,000.00 |
| Mar 31, 2019 | 1.58 Mn |